Improving Detection of EGFR Mutations in Lung Cancer
Author Information
Author(s): Wu Shang-Gin, Chang Yih-Leong, Lin Jou-Wei, Wu Chen-Tu, Chen Hsuan-Yu, Tsai Meng-Feng, Lee Yung-Chie, Yu Chong-Jen, Shih Jin-Yuan
Primary Institution: National Taiwan University Hospital
Hypothesis
Can including total EGFR staining in scoring improve the detection of EGFR mutations and predict response to EGFR TKIs in lung adenocarcinoma patients?
Conclusion
Including total EGFR expression in the IHC interpretation improves the detection of L858R mutations and enhances prediction of clinical outcomes.
Supporting Evidence
- Patients with positive IHC staining had better EGFR TKI response and longer progression-free survival.
- The predictive model based on IHC Q score showed high sensitivity and specificity for detecting mutations.
- Total EGFR expression was found to influence the interpretation of mutation-specific antibodies.
Takeaway
This study shows that checking for total EGFR levels helps doctors find specific mutations in lung cancer better, which can lead to better treatment choices.
Methodology
Patients with surgically resected lung adenocarcinoma were enrolled, and EGFR mutation status was determined using PCR and IHC with mutation-specific antibodies.
Potential Biases
Potential bias in patient selection and the retrospective nature of the study may affect the results.
Limitations
The study may not generalize to all lung cancer patients as it focused on a specific population and used a limited set of mutations.
Participant Demographics
143 patients, median age 65.2 years, 72 females and 71 males, with 65.7% being non-smokers.
Statistical Information
P-Value
p=0.036
Confidence Interval
95% CI not specified
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website